

1 **CMV seropositivity in older adults changes T cell functionality, but does not prevent**  
2 **antibody or cellular SARS-CoV-2 vaccine responses**

3  
4 **Authors:**

5 Jessica A. Breznik<sup>1-4</sup>, Angela Huynh<sup>3</sup>, Ali Zhang<sup>1,2,5</sup>, Lucas Bilaver<sup>1-3</sup>, Hina Bhakta<sup>3</sup>, Hannah D.  
6 Stacey<sup>1,2,5</sup>, Jann C. Ang<sup>1,2,5</sup>, Jonathan L. Bramson<sup>1-3,5</sup>, Ishac Nazy<sup>3,7</sup>, Matthew S. Miller<sup>1,2,5</sup>,  
7 Judah Denburg<sup>3</sup>, Andrew P. Costa<sup>3,9-10</sup> Dawn M. E. Bowdish<sup>1-4,11\*</sup>, and other members of the  
8 COVID-in-LTC Investigator Group  
9

10 <sup>1</sup>McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada, L8S 4K1

11 <sup>2</sup>Michael G. DeGrootte Institute for Infectious Disease Research, McMaster University, Hamilton,  
12 Ontario, Canada, L8S 4K1

13 <sup>3</sup>Department of Medicine, Michael G. DeGrootte School of Medicine, McMaster University, Hamilton,  
14 Ontario, Canada, L8S 4L8

15 <sup>4</sup>McMaster Institute for Research on Aging, McMaster University, Hamilton, Ontario, Canada, L8S 4K1

16 <sup>5</sup>Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada,  
17 L8S 3L8

18 <sup>6</sup>St. Mary's General Hospital, Kitchener, Ontario, Canada, N2M 1B2

19 <sup>7</sup>McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada, L8S 3L8

20 <sup>8</sup>Health Science North Research Institute, Sudbury, Ontario, P3E 2H2

21 <sup>9</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton,  
22 Canada, L8S 3L8

23 <sup>10</sup>Centre for Integrated Care, St. Joseph's Health System, Hamilton, Ontario, Canada, L8N 4A6

24 <sup>11</sup>Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, Ontario, Canada, L8N 4A6  
25

26 **Running title:** Cytomegalovirus and SARS-CoV-2 vaccination

27 **Key words:** COVID-19, SARS-CoV-2, CMV, mRNA vaccine, humoral immunity, cellular  
28 immunity, viral neutralization, vaccine efficacy, older adults  
29

30 **\*Corresponding author:**

31 Dawn Bowdish, PhD

32 M. G. DeGrootte Institute for Infectious Disease Research

33 McMaster Immunology Research Centre

34 McMaster University, MDCL 4020

35 1280 Main Street West

36 Hamilton, Ontario, Canada L8S 4L8

37 Phone: +1-905-525-9140, ext 22313

38 Fax: +1-905-522-6750

39 Email: [bowdish@mcmaster.ca](mailto:bowdish@mcmaster.ca)  
40

41 **Abstract Word Count:** 150 words

42 **Text Word Count:**

43 **Figures:** 4; 9 Supplementary

44 **Tables:** 4

45 **Conflict of Interest Disclosures:** The authors have no financial relationship with any  
46 organization that may have an interest and have no other relationships or activities that could  
47 post a conflict of interest.

48  
49 **Additional Information/Contributions:** Data in this study were collected by the COVID-in-  
50 LTC Study Group. Other members of the COVID-in-LTC Study Group include Eric D. Brown,  
51 Kevin Brown, David C. Bulir, George A. Heckman, Michael P. Hillmer, John P. Hirdes, Aaron  
52 Jones, Mark Loeb, Janet E. McElhaney (posthumous), Nathan M. Stall, Parminder Raina, Marek  
53 Smieja, Ahmad Von Schlegell, Kevin Stinson, Arthur Sweetman, Chris Verschoor, and Gerry  
54 Wright. We acknowledge administrative and technical assistance from Tara Kajaks, Ahmad  
55 Rahim, Komal Aryal, Megan Hagerman, Braeden Cowbrough, Leslie Tan, Sussan Kianpour,  
56 Jodie Turner, and Sheneice Joseph, and funding from the Canadian COVID-19 Immunity Task  
57 Force at McMaster University. We would like to thank our participants and their families, as  
58 well as staff at the assisted living facilities, for their support of this study.

59  
60 **Funding:** This work was funded by a grant from Canadian COVID-19 Immunity Task Force and  
61 Public Health Agency of Canada awarded to Costa and Bowdish. APC is the Schlegel Chair in  
62 Clinical Epidemiology and Aging. DMEB is the Canada Research Chair in Aging & Immunity.  
63 Funding support for this work was provided by grants from the Ontario Research Foundation,  
64 COVID-19 Rapid Research Fund, and by the Canadian COVID-19 Immunity Task Force  
65 awarded to IN. MSM is supported, in part, by an Ontario Early Researcher Award and a Canada  
66 Research Chair in Viral Pandemics.

67 **Abstract**

68 It has been previously reported that chronic infection with human cytomegalovirus (CMV) may  
69 contribute to poor vaccine responses against *de novo* antigens in older adults. We assessed  
70 effects of CMV serostatus on antibody quantity and quality, as well as cellular memory  
71 responses, after 2 and 3 SARS-CoV-2 mRNA vaccine doses, in older adults in congregate living  
72 facilities. CMV serostatus did not affect anti-Spike and anti-RBD IgG antibody levels, nor  
73 neutralization capacity against wildtype or beta variants of SARS-CoV-2. CMV seropositivity  
74 altered T cell expression of senescence-associated markers and increased T<sub>EMRA</sub> cell numbers, as  
75 has been previously reported; however, this did not impact the Spike-specific CD4<sup>+</sup> T cell  
76 memory responses. CMV seropositive individuals did not have a higher incidence of COVID-19,  
77 though prior infection influenced humoral immunity. Therefore, CMV seropositivity may alter T  
78 cell composition but does not impede humoral or cellular memory responses after SARS-CoV-2  
79 mRNA vaccination in older adults.

## 80 Introduction

81 Aging is associated with an increased frequency of viral respiratory infections and post-  
82 infection sequelae<sup>1</sup>, as well as reduced vaccine efficacy<sup>2</sup>. Early in the COVID-19 pandemic, age  
83 was identified to be the most significant factor contributing to morbidity and mortality<sup>3</sup>, and it  
84 was unclear how effective vaccines against the *de novo* SARS-CoV-2 virus would be in older  
85 adults. Older adults often respond well to vaccines that target a memory response (e.g. Herpes  
86 zoster), but vaccines against *de novo* antigens or antigens that are antigenically distant from  
87 previous strains (e.g. some seasonal influenza vaccines) are often less immunogenic<sup>4, 5</sup>.  
88 Fortunately, SARS-CoV-2 mRNA vaccines have been shown to be protective in older adults<sup>6, 7, 8</sup>,  
89 as they are effective at generating cellular and antibody-mediated immunity<sup>9, 10, 11, 12</sup>, though  
90 responses are generally more heterogeneous and wane faster than in younger adults<sup>9, 11</sup>.

91  
92 In older adults, both immunosenescence and inflammation are thought to influence the  
93 immunogenicity and longevity of vaccine responses<sup>13, 14</sup>. Many studies have also implicated  
94 human cytomegalovirus (CMV) as a significant contributor to age-associated immune  
95 dysfunction. CMV is a common and persistent  $\beta$ -herpesvirus, found in ~60-90% of adults  
96 worldwide, and seropositivity increases with age<sup>15, 16</sup>. CMV infection is typically asymptomatic  
97 in immunocompetent individuals, but its accompanying chronic immune activation  
98 fundamentally alters immune cell composition and function. There is a consensus that CMV  
99 seropositivity has a long-term impact on the maturation and composition of immune cells,  
100 including increased numbers and prevalence of CD8<sup>+</sup> T cells, with expansion of virus-specific  
101 effector and memory cells at the expense of naïve T cells<sup>17, 18</sup>. Age-associated  
102 immunosenescence likewise contributes to similar changes within the T cell repertoire, reducing

103 naïve T cells and increasing memory T cell populations, which have impaired proliferation,  
104 differentiation, and effector functions<sup>19, 20</sup>. A dysfunctional T cell repertoire may also have  
105 significant effects on B cell proliferation, differentiation, and maturation<sup>21</sup>. Accordingly, CMV  
106 seropositivity has been implicated as an exacerbating factor in age-associated immune  
107 remodelling and inter-individual immune diversity<sup>22, 23, 24, 25</sup>, as well as a modifying factor that  
108 may compromise infection outcomes and vaccination responses<sup>26</sup>.

109  
110         Though there is little data to date, CMV reactivation in older adults has been suggested to  
111 contribute to more severe COVID-19<sup>27, 28, 29, 30, 31</sup>, as CMV seropositivity has been associated  
112 with impaired antibody and cellular immune responses to infections<sup>32, 33, 34</sup>. However, CMV  
113 seropositivity has also been reported to enhance cellular and antibody immune responses to  
114 unrelated bacteria or viruses, through diversification of CD8<sup>+</sup> T cell receptors and augmentation  
115 of basal inflammation<sup>35, 36, 37, 38</sup>. CMV seropositivity has, in addition, been associated with a  
116 reduced humoral response to inactivated split influenza virus vaccines<sup>39, 40, 41, 42</sup> and viral-vector-  
117 based Ebola vaccines<sup>43</sup>. Yet, a recent meta-analysis reported that there was insufficient evidence  
118 that CMV seropositive individuals have decreased antibody production after influenza  
119 vaccination<sup>44</sup>. Recent data also show that CMV seropositivity in young adults does not affect  
120 antibody or cellular responses after vaccination with the adenovirus-based vector vaccine  
121 ChAdOx1 nCoV-19<sup>45</sup>. These conflicting reports may suggest context and age-dependent effects  
122 of chronic CMV infection on immune function. SARS-CoV-2 mRNA vaccines have been widely  
123 deployed in Canada, particularly in older adults. Whether CMV seropositivity impacts SARS-  
124 CoV-2 mRNA vaccine efficacy is not yet known. Herein we investigated effects of CMV  
125 serostatus on humoral and cellular measures of vaccine responses after 2 and 3 doses of SARS-

126 CoV-2 mRNA vaccines in older adults. We found that CMV serostatus does not impede  
127 antibody or cellular responses to SARS-CoV-2 vaccination in older adults.

128

129

## 130 **Methods**

### 131 *Participant Recruitment and Blood Collection*

132 Blood was collected from 188 participants, 65 years of age and older, in assisted living facilities  
133 (3 retirement homes and 14 nursing homes), in Ontario, Canada, between March and December  
134 2021. All protocols were approved by the Hamilton Integrated Research Ethics Board, and  
135 informed consent was obtained. Venous blood was drawn in anti-coagulant-free vacutainers for  
136 isolation of serum, as per standard protocols<sup>46</sup>. Venous blood was drawn in heparin-coated  
137 vacutainers for immunophenotyping and T cell activation assays. Blood was collected at least 7  
138 days after 2nd and/or 3rd mRNA vaccine doses. Blood was drawn after 2nd and 3rd mRNA  
139 vaccine doses from 47 participants. Participant demographics are summarized in Table 1

140

### 141 *Determination of CMV Serostatus*

142 CMV seropositivity was determined by enzyme-linked immunosorbent assay (ELISA) with the  
143 Human Anti-Cytomegalovirus IgG ELISA Kit (CMV) (Abcam ab108639) as per manufacturer's  
144 instructions. Serum samples from a participant's first blood draw were diluted 1:40 and assessed  
145 in duplicate. Samples with a CMV IgG Index above or equal to the positive standard were  
146 classified as CMV seropositive, whereas samples with a CMV IgG index less than the positive  
147 standard were classified as CMV seronegative.

148

149 ***Whole Blood Immunophenotyping***

150 Circulating immune cell populations were quantitated in whole blood using fluorophore-  
151 conjugated monoclonal antibodies by multicolour flow cytometry with a CytoFLEX LX (4 laser,  
152 Beckman Coulter), as per standard protocols<sup>46, 47, 48</sup>. Count-Bright™ absolute counting beads  
153 (Invitrogen Life Technologies, Carlsbad, CA, USA) were used to determine absolute cell counts.  
154 Data was gated with FlowJo V10.8.1 (TreeStar, Inc.) as previously published<sup>47</sup>. Five main  
155 subsets of human CD8<sup>+</sup> and CD4<sup>+</sup> T cells (Naïve (N), Central Memory (CM), Effector Memory  
156 (EM), Effector Memory re-expressing CD45RA (EMRA), and terminally differentiated (TD))  
157 were identified by their expression of CD45RA, CCR7, CD28 and/or CD57. CD8<sub>N</sub> and CD4<sub>N</sub>  
158 were classified as CD45RA<sup>+</sup>CCR7<sup>+</sup>; CD8<sub>CM</sub> and CD4<sub>CM</sub> as CD45RA<sup>-</sup>CCR7<sup>+</sup>; CD8<sub>EM</sub> and  
159 CD4<sub>EM</sub> as CD45RA<sup>-</sup>CCR7<sup>-</sup>, CD8<sub>EMRA</sub> and CD4<sub>EMRA</sub> as CD45RA<sup>+</sup>CCR7<sup>-</sup>; and CD8<sub>TD</sub> and CD4<sub>TD</sub>  
160 as CD45RA<sup>+</sup>CCR7<sup>-</sup>CD28<sup>-</sup>CD57<sup>+</sup>, as per standard protocols<sup>68</sup>.

161

162 ***Assessment of T Cell Activation Induced Markers (AIMs) for SARS-CoV-2 Peptides***

163 Antigen-specific T cell recall responses were assessed as per established protocols<sup>47</sup> using a  
164 Spike (S) glycoprotein SARS-CoV-2 peptide pool containing overlapping peptides of the  
165 complete immunodominant sequence domain (#130-126-701; Miltenyi Biotec, Bergisch  
166 Gladbach, Germany). Negative control (unstimulated wells) and positive control (polyclonal  
167 stimulation with CytoStim™ (0.5 µL/well, #130-092-173; Miltenyi Biotec, Bergisch Gladbach,  
168 Germany) conditions were included with each sample, as was stimulation with influenza  
169 hemagglutinin (HA) antigens (4 µL; AgriFlu, Alfuria® Tetra Inactivated Influenza Vaccine  
170 2020-2021 season, Seqirus, UK). 100 µL of heparinized venous blood was incubated with an  
171 equal volume of Iscove's Modified Dulbecco's Medium, GlutaMAX™ Supplement (Invitrogen

172 Life Technologies, Carlsbad, CA, USA) and 1  $\mu\text{g}/\text{mL}$  S-antigen for 44 h in 96-well flat bottom  
173 plates at 37 °C. Samples were stained with fluorophore-conjugated monoclonal antibodies and  
174 assessed with a CytoFLEX LX (4 laser, Beckman Coulter, Brea, CA, USA) as previously  
175 described<sup>47</sup>. Data was analyzed with FlowJo V10.1 (TreeStar, Inc.) as previously published<sup>47</sup>.  
176 Antigen-specific T cells (AIM-positive) were identified by co-expression of CD25 and CD134  
177 (OX40) on CD4<sup>+</sup> T cells<sup>49, 50</sup>, and co-expression of CD69 and CD137 (4-1BB) on CD8<sup>+</sup> T cells<sup>51</sup>.  
178 Samples with a T cell frequency of at least 20 events and  $\geq 2$ -fold above an unstimulated sample  
179 (negative control; i.e. stimulation index  $\geq 2$ ), were defined as AIM-positive. Expression of  
180 CXCR3, CCR4 and/or CCR6 was used to identify CD4<sup>+</sup> Th1 (CXCR3<sup>+</sup>CCR6<sup>-</sup>CCR4<sup>-</sup>), Th2  
181 (CXCR3<sup>-</sup>CCR4<sup>+</sup>CCR6<sup>-</sup>), and Th17 (CXCR3<sup>-</sup>CCR4<sup>+</sup>CCR6<sup>+</sup>) CD4<sup>+</sup> T cell subsets.

182

### 183 *Measurements of Anti-SARS-CoV-2 Antibodies and Neutralizing Capacity*

184 Serum anti-SARS-CoV-2 spike (S) protein and receptor binding domain (RBD) IgG, IgA and  
185 IgM antibodies were measured by a validated ELISA as previously described<sup>47, 52</sup>, with assay  
186 cut-off 3 standard deviations above the mean of a pre-COVID-19 population from the same  
187 geographic region. Data are reported as a ratio of observed optical density (OD) to the  
188 determined assay cut-off OD. Antibody neutralization capacity was assessed by cell culture  
189 assays with Vero E6 (ATCC CRL-1586) cells and live SARS-CoV-2, with data reported as  
190 geometric microneutralization titers at 50% (MNT<sub>50</sub>), which ranged from below detection  
191 (MNT<sub>50</sub> = 5; 1:10 dilution) to MNT<sub>50</sub> = 1280<sup>52</sup>. Antibody neutralization was measured against  
192 the ancestral strain of SARS-CoV-2 and the beta variant of concern (B.1.351). The beta variant  
193 was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-



194 19/South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de  
195 Oliveira.

196

### 197 *Statistical Analysis*

198 Statistical analyses were conducted using GraphPad Prism version 9 (San Diego, CA, USA).

199 Two-group comparisons of dose and CMV seropositivity or prior COVID-19 and CMV

200 seropositivity were assessed by two-way ANOVA. Differences between CMV seropositive and

201 seronegative group antibody levels, antibody neutralization capacity, T cell immune cell

202 composition, T cell surface expression, and memory T cell responses, were assessed by Student's

203 t-test with Welch's correction or Mann-Whitney U-test, according to data normality. P values are

204 reported as two-tailed and p values less than 0.05 were considered significant.

205

206

### 207 **Results**

#### 208 *Participant demographics*

209 Serum anti-CMV IgG antibodies were measured by ELISA to determine CMV

210 seropositivity. 69.7% (n = 131/188) of participants were CMV seropositive. There was no

211 difference in age or sex distribution between seropositive (median 85±6.8 years, 67.6% female)

212 and seronegative participants (median 86±7.7 years, 69.8% female) (Table 1). Blood samples

213 were collected at a median of 179.8 days (CMV seronegative) and 175.4 days (CMV

214 seronegative) after 2 doses of Moderna Spikevax 100 µg (mRNA-1273) or Pfizer Cominarty 30

215 µg (BNT162b2) administered as per manufacturer-recommended schedules. In Ontario, Canada,

216 3<sup>rd</sup> dose vaccinations were recommended for older adults in congregate living beginning in

217 August 2021, if they were more than 6 months post-2<sup>nd</sup> vaccinations<sup>53</sup>. Participants received 3<sup>rd</sup>

218 doses in August-September 2021, and blood samples were collected at a median of 82.0 days  
219 (CMV seronegative) or 83.7 days (CMV seropositive) after 3<sup>rd</sup> doses. Participants were classified  
220 as having had a previous SARS-CoV-2 infection if they had a documented positive PCR test or  
221 were seropositive for IgG or IgA nucleocapsid antibodies. 37.8% of CMV seronegative  
222 participants and 34.4% of CMV seropositive participants had a positive nasopharyngeal PCR test  
223 since March 2020 and/or serum anti-nucleocapsid IgG or IgA antibodies.

224

225 ***CMV seropositivity does not impede anti-SARS-CoV-2 antibody production or neutralization***  
226 ***in older adults***

227 To assess effects of CMV serostatus on antibody responses after SARS-CoV-2  
228 vaccination, serum anti-SARS-CoV-2 Spike and RBD IgG, IgA, and IgM antibody levels were  
229 measured by ELISA (Figure 1; Table 2). The number of responders (i.e. individuals with  
230 antibodies above the threshold limit of detection) significantly increased between post-2<sup>nd</sup> and  
231 post-3<sup>rd</sup> doses for anti-Spike IgG, IgA, and IgM antibodies, as well as anti-RBD IgG antibodies,  
232 but not anti-RBD IgA or IgM antibodies (Table 2). For example, 5-7 months after second dose  
233 vaccinations, anti-Spike IgG antibody responses were detected in 88.7% of participants, and anti-  
234 RBD IgG antibody responses were detected in 63.5% of participants. Approximately 3 months  
235 after the third dose, 97.3% and 94.6% of participants had detectable anti-Spike IgG and anti-  
236 RBD IgG, respectively. CMV seropositivity did not impact the frequency of responders for anti-  
237 Spike and anti-RBD IgG, IgA, and IgM antibodies. Accordingly, two-group analyses showed a  
238 main effect of vaccine dose, but not CMV serostatus, on serum anti-Spike IgG (Figure 1A) and  
239 anti-RBD (Figure 1D) antibodies, as well as anti-Spike IgA (Figure 1B) and anti-Spike IgM  
240 (Figure 1C) antibodies. There were no significant main effects of vaccine dose or CMV

241 serostatus on anti-RBD IgM (Figure 1F) antibodies. Main effects of dose and CMV serostatus  
242 were observed for serum anti-RBD IgA levels (Figure 1E), though post-hoc assessments by  
243 CMV serostatus were not significant. Therefore, CMV seropositivity does not impede antiviral  
244 antibody responses after SARS-CoV-2 vaccination.

245

246 To examine potential effects of CMV serostatus on antibody function, serum antibody  
247 neutralization capacity was assessed by MNT50 assays against live ancestral (wildtype) and beta  
248 variant SARS-CoV-2 (Figure 1G-H; Table 3). Vaccines were designed against the wildtype  
249 virus, whereas the beta variant contains mutations that confer increased transmissibility and  
250 immune evasion<sup>54</sup>. Neutralization of ancestral and beta variant SARS-CoV-2 ranged from below  
251 the detection limit to MNT50=1280, though mean neutralization was consistently higher against  
252 the ancestral virus after 2 and 3 vaccine doses. Neutralization capacity was similar between  
253 CMV seropositive and seronegative individuals against both ancestral and beta variant SARS-  
254 CoV-2, though there was a main effect of dose on neutralization capacity. In particular,  
255 significant increases in neutralization were observed after 3<sup>rd</sup> dose vaccination against the beta  
256 variant. Anti-Spike and anti-RBD IgG levels moderately correlated with antibody neutralization  
257 capacity, irrespective of CMV serostatus (Table 3). As well, modest correlations were observed  
258 between neutralization capacity and anti-Spike and anti-RBD IgA antibodies in both CMV  
259 seropositive and CMV seronegative participants. Therefore, CMV seropositivity does not  
260 compromise vaccine-elicited antibody neutralization of SARS-CoV-2.

261

262 As serum was collected from some participants after both 2<sup>nd</sup> and 3<sup>rd</sup> vaccine doses, these  
263 paired data were also assessed independently (Supplementary Figure 1). Consistent with our

264 pooled participant data, there were main effects of dose but not CMV serostatus on anti-Spike  
265 and anti-RBD IgG and IgA serum antibody levels. We did observe an interaction between CMV  
266 serostatus and dose on anti-RBD IgM measurements by intra-individual analysis, but most  
267 participants had antibody levels below the threshold. Intra-individual analyses also showed that  
268 the number of vaccine doses, but not CMV serostatus, had a significant effect on antibody  
269 neutralization capacity against wildtype and beta variant virus. Therefore, CMV seropositivity  
270 does not significantly impact intra-individual changes in antibody levels or neutralization  
271 capacity between 2 and 3 doses of SARS-CoV-2 mRNA vaccines.

272  
273 We next considered post-dose 2 and post-dose 3 antibody measurements in context of  
274 prior SARS-CoV-2 infection (Supplementary Figure 2). As summarized in Table 1, incidence of  
275 COVID-19 was similar between CMV seronegative and seropositive participants. We observed a  
276 main effect of prior SARS-CoV-2 infection on anti-Spike and anti-RBD IgG, IgA, and IgM  
277 antibodies after 2 doses of mRNA vaccines, as well as anti-Spike and anti-RBD IgG and IgA, but  
278 not IgM, serum antibodies after 3 vaccine doses. We observed an interaction between prior  
279 COVID-19 and CMV serostatus for anti-Spike and anti-RBD IgA antibodies post-dose 2 and  
280 post-dose 3, and IgM antibodies post-dose 2. There was a main effect of CMV serostatus on anti-  
281 Spike IgM antibodies, but as observed above, most individuals had levels below the detection  
282 threshold. We in addition observed main effects of prior SARS-CoV-2 infection, but not CMV  
283 serostatus, on antibody neutralization of ancestral SARs-CoV-2 after 2 and 3 vaccine doses and  
284 the beta variant after 2, but not 3, vaccine doses (Supplementary Figure 3). Collectively, these  
285 data indicate that CMV serostatus does not appear to have a major impact on anti-Spike or anti-  
286 RBD IgG antibody production, or total serum antibody neutralization capacity. Moreover, CMV

287 seropositivity in the older adult cohort did not impair IgG antibody production or neutralization  
288 in response to SARS-CoV-2 vaccination.

289

### 290 *CMV serostatus influences peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cell immunophenotype*

291 To examine the impact of CMV seropositivity on the T cell repertoire, whole blood CD4<sup>+</sup>  
292 and CD8<sup>+</sup> T cell composition was quantitated, and their surface expression of CD28 and CD57  
293 was measured, by flow cytometry (Figure 2; Supplementary Figure 4). Chronic T cell activation  
294 is a characteristic of CMV seropositivity<sup>18, 36, 55</sup>. Accordingly, CMV seropositive individuals had  
295 significant changes to their peripheral T cell repertoire (Figure 2; Supplementary Figure 4). We  
296 found no changes in numbers of circulating total leukocytes, total CD4<sup>+</sup> T cells, or CD4<sub>N</sub>,  
297 CD4<sub>EM</sub>, CD8<sub>N</sub>, or CD8<sub>EM</sub> T cell populations by CMV serostatus. However, CMV seropositivity  
298 increased numbers of total CD8<sup>+</sup> T cells, as well as CD4<sub>EMRA</sub>, CD4<sub>TD</sub>, CD8<sub>EMRA</sub>, and CD8<sub>TD</sub> T  
299 cells, and decreased numbers of CD4<sub>CM</sub> and CD8<sub>CM</sub> T cells (Figure 2).

300

301 CD28 is a co-stimulatory molecule that contributes to TCR-antigen-mediated activation  
302 of T cells, while CD57 is a marker of terminally differentiated T cells as well as an indicator of  
303 immune senescence<sup>56</sup>. Repeated T cell activation is associated with upregulation of CD57 and a  
304 reduction in CD28 expression<sup>57, 58, 59</sup>. Consistent with these prior data, comparisons of CD28 and  
305 CD57 expression on T cell populations by CMV serostatus in our cohort of older adults (Figure  
306 2O) revealed increased CD57 expression and reduced CD28 expression on total CD4<sup>+</sup> and CD8<sup>+</sup>  
307 T cell populations, as well as more specifically CD4<sub>CM</sub>, CD4<sub>EM</sub>, CD4<sub>EMRA</sub>, CD8<sub>N</sub>, and CD8<sub>EMRA</sub>  
308 T cells. Expression of CD28 was also decreased on CD8<sub>CM</sub> and CD8<sub>EM</sub> cells of CMV

309 seropositive individuals, though expression of CD57 was not influenced by CMV serostatus.  
310 CMV serostatus did not affect CD57 or CD28 expression on CD4<sub>N</sub> T cells.

311  
312 As even mild COVID-19 can have lasting effects on immune cell composition<sup>47</sup>, we also  
313 considered combined effects of prior SARS-CoV-2 infection and CMV serostatus on T cell  
314 composition (Supplementary Figures 5-6). Prior SARS-CoV-2 infection was associated with  
315 lower leukocyte counts, but otherwise had no significant main effects on absolute cell numbers  
316 nor prevalence of the assessed CD4<sup>+</sup> or CD8<sup>+</sup> T cell populations.

317  
318 In summary, there are significant changes to the relative composition and functional  
319 phenotype of peripheral blood CD8<sup>+</sup> T cell and CD4<sup>+</sup> T cell subsets between CMV seronegative  
320 and seropositive individuals, irrespective of prior COVID-19. The observed expansion of EMRA  
321 and terminally differentiated T cells, as well as reduced surface expression of the costimulatory  
322 molecule CD28 on CD8<sub>N</sub> T cells in particular, may influence T cell vaccine responses.

323  
324 ***CMV serostatus influences CD4<sup>+</sup> and CD8<sup>+</sup> SARS-CoV-2 antigen-induced recall responses***

325 An activation-induced marker (AIM) assay was used to examine T cell memory  
326 responses after second and third dose SARS-CoV-2 mRNA vaccinations (Figure 3; Table 4).  
327 SARS-CoV-2 vaccines are unusual in that healthy adults generate strong CD4<sup>+</sup> T cell memory  
328 recall responses, but weaker CD8<sup>+</sup> T cell memory responses<sup>60</sup>. We also made similar  
329 observations in older adults. Most study participants had CD4<sup>+</sup> T cell responses to SARS-CoV-2  
330 Spike (post-dose 2: 93.1%; post-dose 3: 95.9%), but only 19.5% of participants had Spike-  
331 elicited CD8<sup>+</sup> memory T cell responses after 2 vaccine doses, though this increased to 29.7% of

332 participants after 3 vaccine doses. CMV serostatus did not influence the number of individuals  
333 with SARS-CoV-2 Spike-activated CD4<sup>+</sup> T cells or CD8<sup>+</sup> T cells after 2<sup>nd</sup> or 3<sup>rd</sup> dose  
334 vaccinations. Grouped analyses revealed a significant main effect of CMV serostatus on the  
335 frequency of S-CD8<sup>+</sup> T cells. However, despite greater variance of data in seropositive  
336 individuals, post-hoc analyses by CMV serostatus were not significant post-dose 2 or post-dose  
337 3. Intra-individual paired analyses also showed no main effects of vaccine dose nor CMV  
338 serostatus on S-CD8<sup>+</sup> T cell population activation (Supplementary Figure 7). Prior COVID-19  
339 did not influence the prevalence of S-CD8<sup>+</sup> T cells after 2 or 3 vaccine doses, though CMV  
340 seropositivity contributed to increased S-CD8<sup>+</sup> T cell activation post-dose 2 (Supplementary  
341 Figure 8). The prevalence of S-activated CD4<sup>+</sup> T cells was likewise not different by CMV  
342 serostatus (Figure 3B), nor prior COVID-19 (Supplementary Figure 8), though grouped analyses  
343 on a population and intra-individual basis showed a main effect of vaccine dose (Supplementary  
344 Figure 7). Therefore, CMV serostatus contributes to increased CD8<sup>+</sup> T cell, but not CD4<sup>+</sup> T cell,  
345 memory responses to SARS-CoV-2 Spike antigen.

346  
347 CD4<sup>+</sup> memory T cells are comprised of a number of different functional subsets,  
348 including T helper 1 (Th1), T helper 2 (Th2), and T helper 17 (Th17) cells<sup>61</sup>, which were further  
349 characterized. There was a significant effect of CMV serostatus on the frequency of Th1 S-CD4<sup>+</sup>  
350 T cells, with post-hoc analyses showing an increase in CMV seropositive individuals after 2 but  
351 not 3 vaccine doses (Figure 3C). Th2 and Th17 S-CD4<sup>+</sup> T cell frequencies were not influenced  
352 by CMV serostatus (Figure 3D-E), though paired analyses by dose and CMV serostatus  
353 suggested a significant increase in Th17 responses in CMV seropositive individuals after 3<sup>rd</sup>  
354 vaccine doses (Supplementary Figure 7). Interestingly, when we considered these data in context

355 of prior SARS-CoV-2 infection, CMV serostatus had a main effect on the prevalence of S-CD4<sup>+</sup>  
356 Th1 and Th17 T cells, which increased and decreased, respectively, with CMV seropositivity,  
357 though only post-dose 2 (Supplementary Figure 8).

358  
359 To determine if the observed contributions of CMV serostatus to increased CD8<sup>+</sup> T cell  
360 and CD4<sup>+</sup> Th1 T cell memory responses are consistent across different stimuli, we also examined  
361 T cell AIM responses after TCR-independent polyclonal stimulation with CytoStim, and  
362 stimulation with influenza hemagglutinin antigens (Figure 4). As we observed for Spike-  
363 activated T cells, both CytoStim and HA stimulation resulted in increased proportions of  
364 AIM<sup>+</sup>CD8<sup>+</sup> T cells in CMV seropositive individuals (Figure 4A, 4F), though AIM<sup>+</sup>CD4<sup>+</sup> T cell  
365 frequency was not affected by CMV serostatus (Figure 4B, 4G). These data show that effects of  
366 CMV seropositivity on total AIM<sup>+</sup>CD8<sup>+</sup> and AIM<sup>+</sup>CD4<sup>+</sup> T cell frequencies are consistent across  
367 different stimuli. CytoStim-stimulated CD4<sup>+</sup> T cells, like Spike-stimulated CD4<sup>+</sup> T cells, also  
368 showed distinct Th1 skewed responses, though this was not observed after HA stimulation.  
369 These data collectively suggest that CMV serostatus alters the functional composition of memory  
370 T cells, with antigen-specific effects, though CMV serostatus but does not alter the ability of  
371 older adults to generate CD4<sup>+</sup> or CD8<sup>+</sup> T cell memory, nor the incidence of activation after  
372 SARS-CoV-2 vaccination.

373

374

## 375 **Discussion**

376 Our data suggest that despite being a significant modifier of peripheral blood T cell  
377 composition and phenotype, CMV seropositivity does not have a negative impact on vaccine  
378 immunogenicity in older adults. Yet, we found that there were subtle changes in antibody and



379 cellular responses in CMV seropositive individuals between vaccine doses and in individuals  
380 with prior COVID-19. Our study cohort included participants from multiple assisted living  
381 facilities, and it did not exclude individuals with particular health conditions (e.g. cancer,  
382 diabetes, cardiovascular disease, autoimmune disorders) or prescribed medications (e.g. immune  
383 modulating drugs). Thus, any observed effects of CMV needed to be sufficiently robust to  
384 overcome potential effects of those other factors.

385  
386 Our observations of changes in the peripheral T cell repertoire in CMV seropositive  
387 individuals, and CD4<sup>+</sup> and CD8<sup>+</sup> T cell expression of CD28 and CD57, are consistent with prior  
388 publications that reported expansion of exhausted CD4<sub>EMRA</sub> and CD8<sub>EMRA</sub> memory T cells in  
389 CMV seropositive healthy community-dwelling adults<sup>39, 41</sup>. There are conflicting reports as to  
390 whether the CMV seropositivity is associated with a reduction in naïve CD4<sup>+</sup> and CD8<sup>+</sup> T cells.  
391 In this investigation, we observed similar numbers of CD4<sub>N</sub> and CD8<sub>N</sub> T cells in seropositive and  
392 seronegative individuals, and in particular similar expression of CD57 and CD28 on CD4<sub>N</sub> T  
393 cells. Our data therefore suggest that CMV seropositivity does not influence the availability nor  
394 capacity of circulating naïve T cells to respond and generate memory responses to *de novo*  
395 antigens in older adults.

396  
397 CMV seropositivity in older adults has been associated with lower frequencies of  
398 memory T cells in response to seasonal influenza, though acute infection T cell responses were  
399 unchanged<sup>62</sup>, and there is conflicting data as to whether CMV seropositivity enhances or impairs  
400 influenza virus-specific T cell responses<sup>31, 39, 63, 64</sup>. We found that T cell memory recall responses  
401 were similar in CMV seropositive and seronegative individuals. Our findings are concordant

402 with observations from a previous study that found CMV serostatus did not alter the ability of  
403 older adults to generate memory responses to the newly emergent (at the time) West Nile virus<sup>46</sup>.  
404 We observed in our cohort of older adults that T cell memory responses were not different by  
405 CMV serostatus. Furthermore, it has been reported that T cell memory responses to the SARS-  
406 CoV-2 Spike protein are boosted in convalescent younger adults after vaccination<sup>65, 66</sup>. We  
407 identified an increase in Spike-specific CD4<sup>+</sup> T cell memory responses between 2 and 3 mRNA  
408 vaccine doses in our older adult cohort, but we did not observe increased CD8<sup>+</sup> or CD4<sup>+</sup> T cell  
409 memory responses in convalescent older adults after vaccination. This may in part be because  
410 our analysis of effects of prior COVID-19 were not restricted to a particular time frame post-  
411 SARS-CoV-2 infection. Irrespective, these findings suggest that while combined effects of  
412 infection and subsequent vaccination may differ by age, older adults can elicit functional  
413 memory T cell responses to infection and vaccination against *de novo* viruses.

414

415 We observed a distinct Th1 bias after polyclonal T cell activation, and in response to the  
416 immunodominant regions of the Spike antigen after 2 doses, but not 3 doses, of SARS-CoV-2  
417 mRNA vaccines. Th1 skewing of the immune response after influenza virus vaccination has been  
418 previously noted in CMV seropositive infants and young adults and mice<sup>64, 67</sup>, as well as in older  
419 adults<sup>68</sup>. Strong Th1 CD4<sup>+</sup> T cell responses have been associated with lower disease severity in  
420 unvaccinated COVID-19 patients<sup>69</sup>, and SARS-CoV-2 Spike-elicited CD4<sup>+</sup> T cell memory  
421 responses in unvaccinated convalescent individuals have also been identified to be primarily  
422 Th1-differentiated<sup>65, 66</sup>. However, we did not identify a main effect of prior COVID-19, nor an  
423 interaction of CMV serostatus and prior COVID-19, on the prevalence of CD4<sup>+</sup> T cell Th1  
424 responses in vaccinated older adults. These data indicate that in older adults CMV seropositivity

425 is associated with Th1-biased CD4<sup>+</sup> T cell responses, which are not further modified by any prior  
426 SARS-CoV-2 infection. Our observations also suggest that Spike-specific memory T cell  
427 functional responses change between 2 and 3 vaccine doses in older adults, congruent with  
428 observations of changes in memory T cell phenotype between vaccine doses in younger adults<sup>65</sup>.

430 Our data also show that CMV seropositivity does not prevent production of anti-Spike or  
431 anti-RBD IgG, IgA, or IgM antibodies after SARS-CoV-2 mRNA, though we did observe an  
432 interaction between CMV seropositivity and prior COVID-19 both post-dose 2 and post-dose 3.  
433 These effects may be reflective of our limited sample size, or differences in time since infection  
434 between CMV seropositive and CMV seronegative individuals. CMV seropositive individuals  
435 have been reported to have increased B cell proliferation and mutations within the  
436 immunoglobulin heavy chain sequences of IgM and IgG, but not IgA, isotypes<sup>70</sup>. CMV  
437 serostatus could also have a larger effect on maturation of the antibody response via isotype  
438 switching, and thus isotype composition after vaccination, which may contribute to our  
439 observations, but to our knowledge this has not been extensively explored.

441 Early in the pandemic, CMV seropositivity was associated with increased risk of  
442 hospitalization in COVID-19 patients<sup>71</sup>, and CMV reactivation was later reported to have a  
443 higher incidence in patients in intensive care<sup>72</sup>. More recently it was reported that unvaccinated  
444 individuals with latent CMV, irrespective of anti-CMV antibody levels, age, and sex, are at  
445 higher risk of SARS-CoV-2 infection and hospitalization<sup>73</sup>. In particular, the exhausted T cells  
446 present in CMV seropositive individuals have also been predicted to contribute to more severe  
447 COVID-19 pathophysiology<sup>74</sup>. Our data does not preclude the possibility that CMV-associated

448 remodelling of innate and adaptive immunity in older adults may contribute to the pathogenesis  
449 and severity of SARS-CoV-2 infection. CMV serostatus may in addition impact humoral or  
450 cellular responses to breakthrough infections with current or emerging variants of concern.

451

452         In conclusion, our data shows that CMV serostatus alters the T cell repertoire but does  
453 not blunt cellular nor humoral responses after 2 and 3 doses SARS-CoV-2 mRNA vaccines in  
454 older adults in congregate care facilities. Further research is necessary to disentangle the more  
455 subtle effects of CMV serostatus on immunogenicity and durability of immune responses after  
456 vaccination, as well as to assess its role in risk of breakthrough infections.

457

458 **References**

- 459
- 460 1. Kline, K.A. & Bowdish, D.M. Infection in an aging population. *Current opinion in*  
461 *microbiology* **29**, 63-67 (2016).
- 462
- 463 2. Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in  
464 the elderly: a quantitative review. *Vaccine* **24**, 1159-1169 (2006).
- 465
- 466 3. Banerjee, A. *et al.* Estimating excess 1-year mortality associated with the COVID-19  
467 pandemic according to underlying conditions and age: a population-based cohort study.  
468 *Lancet* **395**, 1715-1725 (2020).
- 469
- 470 4. Cunningham, A.L. *et al.* Efficacy of the herpes zoster subunit vaccine in adults 70 years  
471 of age or older. *New England Journal of Medicine* **375**, 1019-1032 (2016).
- 472
- 473 5. Lal, H. *et al.* Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. *The*  
474 *New England journal of medicine* **372**, 2087-2096 (2015).
- 475
- 476 6. Brown, K., Stall, NM., Vanniyasingam T., et al. Early impact of Ontario’s COVID-19  
477 vaccine rollout on long-term care home residents and health care workers. Science Briefs  
478 of the Ontario COVID-19 Science Advisory Table; 2021.
- 479
- 480 7. Salcher-Konrad, M., Smith, S. & Comas-Herrera, A. Emerging Evidence on  
481 Effectiveness of COVID-19 Vaccines Among Residents of Long-Term Care Facilities.  
482 *Journal of the American Medical Directors Association* **22**, 1602-1603 (2021).
- 483
- 484 8. Chung, H. *et al.* Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against  
485 symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada:  
486 test negative design study. *BMJ* **374**, n1943 (2021).
- 487
- 488 9. Breznik, J.A. *et al.* Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273  
489 or BNT163b2 in Nursing Home Residents. *medRxiv*, 2021.2008.2017.21262152 (2021).
- 490
- 491 10. Zhang, A. *et al.* Antibody Responses to 3rd Dose mRNA Vaccines in Nursing Home and  
492 Assisted Living Residents. *medRxiv*, 2021.2012.2017.21267996 (2021).
- 493
- 494 11. Brockman, M.A. *et al.* Reduced magnitude and durability of humoral immune responses  
495 to COVID-19 mRNA vaccines among older adults. *J Infect Dis* (2021).
- 496
- 497 12. Weng, N.-p. & Pawelec, G. Validation of the effectiveness of SARS-CoV-2 vaccines in  
498 older adults in “real-world” settings. *Immunity & Ageing* **18**, 36 (2021).
- 499
- 500 13. Fulop, T. *et al.* Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin:  
501 Friends or Foes? *Front Immunol* **8**, 1960-1960 (2018).
- 502

- 503 14. Fulop, T., Pawelec, G., Castle, S. & Loeb, M. Immunosenescence and vaccination in  
504 nursing home residents. *Clinical infectious diseases : an official publication of the*  
505 *Infectious Diseases Society of America* **48**, 443-448 (2009).  
506
- 507 15. Zuhair, M. *et al.* Estimation of the worldwide seroprevalence of cytomegalovirus: A  
508 systematic review and meta-analysis. *Reviews in medical virology* **29**, e2034 (2019).  
509
- 510 16. Pawelec, G., McElhaney, J.E., Aiello, A.E. & Derhovanessian, E. The impact of CMV  
511 infection on survival in older humans. *Curr Opin Immunol* **24**, 507-511 (2012).  
512
- 513 17. Sylwester, A.W. *et al.* Broadly targeted human cytomegalovirus-specific CD4+ and  
514 CD8+ T cells dominate the memory compartments of exposed subjects. *Journal of*  
515 *Experimental Medicine* **202**, 673-685 (2005).  
516
- 517 18. Chidrawar, S. *et al.* Cytomegalovirus-seropositivity has a profound influence on the  
518 magnitude of major lymphoid subsets within healthy individuals. *Clinical and*  
519 *experimental immunology* **155**, 423-432 (2009).  
520
- 521 19. Sansoni, P. *et al.* The immune system in extreme longevity. *Experimental gerontology*  
522 **43**, 61-65 (2008).  
523
- 524 20. Goronzy, J.J. & Weyand, C.M. Successful and Maladaptive T Cell Aging. *Immunity* **46**,  
525 364-378 (2017).  
526
- 527 21. Dörner, T. & Radbruch, A. Antibodies and B Cell Memory in Viral Immunity. *Immunity*  
528 **27**, 384-392 (2007).  
529
- 530 22. Yan, Z. *et al.* Aging and CMV discordance are associated with increased immune  
531 diversity between monozygotic twins. *Immunity & ageing : I & A* **18**, 5 (2021).  
532
- 533 23. Brodin, P. *et al.* Variation in the human immune system is largely driven by non-heritable  
534 influences. *Cell* **160**, 37-47 (2015).  
535
- 536 24. Mekker, A. *et al.* Immune senescence: relative contributions of age and cytomegalovirus  
537 infection. *PLoS pathogens* **8**, e1002850 (2012).  
538
- 539 25. Olsson, J. *et al.* Age-related change in peripheral blood T-lymphocyte subpopulations and  
540 cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune  
541 study. *Mechanisms of ageing and development* **121**, 187-201 (2000).  
542
- 543 26. Croke, S.N., Ovsyannikova, I.G., Poland, G.A. & Kennedy, R.B. Immunosenescence  
544 and human vaccine immune responses. *Immunity & Ageing* **16**, 25 (2019).  
545
- 546 27. Kadambari, S., Klenerman, P. & Pollard, A.J. Why the elderly appear to be more severely  
547 affected by COVID-19: The potential role of immunosenescence and CMV. *Reviews in*  
548 *medical virology* **30**, e2144 (2020).

- 549  
550 28. Moss, P. "The ancient and the new": is there an interaction between cytomegalovirus and  
551 SARS-CoV-2 infection? *Immunity & ageing : I & A* **17**, 14-14 (2020).  
552
- 553 29. Söderberg-Nauclér, C. Does reactivation of cytomegalovirus contribute to severe  
554 COVID-19 disease? *Immunity & ageing : I & A* **18**, 12-12 (2021).  
555
- 556 30. Chen, Y. *et al.* Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing*  
557 *research reviews* **65**, 101205 (2021).  
558
- 559 31. Merani, S., Pawelec, G., Kuchel, G.A. & McElhane, J.E. Impact of Aging and  
560 Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.  
561 *Front Immunol* **8**, 784 (2017).  
562
- 563 32. Cicin-Sain, L. *et al.* Cytomegalovirus infection impairs immune responses and  
564 accentuates T-cell pool changes observed in mice with aging. *PLoS pathogens* **8**,  
565 e1002849 (2012).  
566
- 567 33. Smithey, M.J., Li, G., Venturi, V., Davenport, M.P. & Nikolich-Zugich, J. Lifelong  
568 persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in  
569 late life. *J Immunol* **189**, 5356-5366 (2012).  
570
- 571 34. Khan, N. *et al.* Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus  
572 impairs the response to a coresident EBV infection. *J Immunol* **173**, 7481-7489 (2004).  
573
- 574 35. Barton, E.S. *et al.* Herpesvirus latency confers symbiotic protection from bacterial  
575 infection. *Nature* **447**, 326-329 (2007).  
576
- 577 36. Terrazzini, N. *et al.* Cytomegalovirus infection modulates the phenotype and functional  
578 profile of the T-cell immune response to mycobacterial antigens in older life.  
579 *Experimental gerontology* **54**, 94-100 (2014).  
580
- 581 37. Pera, A. *et al.* CMV latent infection improves CD8+ T response to SEB due to expansion  
582 of polyfunctional CD57+ cells in young individuals. *PloS one* **9**, e88538 (2014).  
583
- 584 38. Smithey, M.J. *et al.* Lifelong CMV infection improves immune defense in old mice by  
585 broadening the mobilized TCR repertoire against third-party infection. *Proceedings of the*  
586 *National Academy of Sciences of the United States of America* **115**, E6817-e6825 (2018).  
587
- 588 39. Derhovanessian, E. *et al.* Cytomegalovirus-associated accumulation of late-differentiated  
589 CD4 T-cells correlates with poor humoral response to influenza vaccination. *Vaccine* **31**,  
590 685-690 (2013).  
591
- 592 40. Saurwein-Teissl, M. *et al.* Lack of antibody production following immunization in old  
593 age: association with CD8+ CD28- T cell clonal expansions and an imbalance in the



- 594 production of Th1 and Th2 cytokines. *The Journal of Immunology* **168**, 5893-5899  
595 (2002).  
596
- 597 41. Frasca, D., Diaz, A., Romero, M., Landin, A.M. & Blomberg, B.B. Cytomegalovirus  
598 (CMV) seropositivity decreases B cell responses to the influenza vaccine. *Vaccine* **33**,  
599 1433-1439 (2015).  
600
- 601 42. Trzonkowski, P. *et al.* Association between cytomegalovirus infection, enhanced  
602 proinflammatory response and low level of anti-hemagglutinins during the anti-influenza  
603 vaccination--an impact of immunosenescence. *Vaccine* **21**, 3826-3836 (2003).  
604
- 605 43. Bowyer, G. *et al.* Reduced Ebola vaccine responses in CMV+ young adults is associated  
606 with expansion of CD57+KLRG1+ T cells. *J Exp Med* **217**, e20200004 (2020).  
607
- 608 44. van den Berg, S.P.H., Warmink, K., Borghans, J.A.M., Knol, M.J. & van Baarle, D.  
609 Effect of latent cytomegalovirus infection on the antibody response to influenza  
610 vaccination: a systematic review and meta-analysis. *Medical microbiology and*  
611 *immunology* **208**, 305-321 (2019).  
612
- 613 45. Sharpe, H.R. *et al.* CMV-associated T cell and NK cell terminal differentiation does not  
614 affect immunogenicity of ChAdOx1 vaccination. *JCI Insight* **7** (2022).  
615
- 616 46. Verschoor, C.P., Kohli, V. & Balion, C. A comprehensive assessment of  
617 immunophenotyping performed in cryopreserved peripheral whole blood. *Cytometry B*  
618 *Clin Cytom* **94**, 662-670 (2018).  
619
- 620 47. Kennedy, A.E. *et al.* Lasting Changes to Circulating Leukocytes in People with Mild  
621 SARS-CoV-2 Infections. *Viruses* **13**, 2239 (2021).  
622
- 623 48. Loukov, D., Karampatos, S., Maly, M.R. & Bowdish, D.M.E. Monocyte activation is  
624 elevated in women with knee-osteoarthritis and associated with inflammation, BMI and  
625 pain. *Osteoarthritis Cartilage* **26**, 255-263 (2018).  
626
- 627 49. Zaunders, J.J. *et al.* High levels of human antigen-specific CD4+ T cells in peripheral  
628 blood revealed by stimulated coexpression of CD25 and CD134 (OX40). *J Immunol* **183**,  
629 2827-2836 (2009).  
630
- 631 50. Seddiki, N. *et al.* Human antigen-specific CD4(+) CD25(+) CD134(+) CD39(+) T cells  
632 are enriched for regulatory T cells and comprise a substantial proportion of recall  
633 responses. *Eur J Immunol* **44**, 1644-1661 (2014).  
634
- 635 51. Wolfl, M. *et al.* Activation-induced expression of CD137 permits detection, isolation, and  
636 expansion of the full repertoire of CD8+ T cells responding to antigen without requiring  
637 knowledge of epitope specificities. *Blood* **110**, 201-210 (2007).  
638



- 639 52. Huynh, A. *et al.* Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-  
640 19 Subjects. *Viruses* **13**, 697 (2021).  
641
- 642 53. Immunization, N.A.C.o. Guidance on booster COVID-19 vaccine doses in Canada -  
643 Update December 3, 2021: Public Health Agency of Canada; 2021.  
644
- 645 54. Hirabara, S.M. *et al.* SARS-COV-2 Variants: Differences and Potential of Immune  
646 Evasion. *Frontiers in cellular and infection microbiology* **11**, 781429 (2021).  
647
- 648 55. Klenerman, P. & Oxenius, A. T cell responses to cytomegalovirus. *Nature reviews.*  
649 *Immunology* **16**, 367-377 (2016).  
650
- 651 56. Strioga, M., Pasukoniene, V. & Characiejus, D. CD8+ CD28- and CD8+ CD57+ T cells  
652 and their role in health and disease. *Immunology* **134**, 17-32 (2011).  
653
- 654 57. Fletcher, J.M. *et al.* Cytomegalovirus-specific CD4+ T cells in healthy carriers are  
655 continuously driven to replicative exhaustion. *The Journal of Immunology* **175**, 8218-  
656 8225 (2005).  
657
- 658 58. Henson, S.M., Riddell, N.E. & Akbar, A.N. Properties of end-stage human T cells  
659 defined by CD45RA re-expression. *Curr Opin Immunol* **24**, 476-481 (2012).  
660
- 661 59. Brenchley, J.M. *et al.* Expression of CD57 defines replicative senescence and antigen-  
662 induced apoptotic death of CD8+ T cells. *Blood, The Journal of the American Society of*  
663 *Hematology* **101**, 2711-2720 (2003).  
664
- 665 60. Neidleman, J. *et al.* mRNA vaccine-induced T cells respond identically to SARS-CoV-2  
666 variants of concern but differ in longevity and homing properties depending on prior  
667 infection status. *eLife* **10**, e72619 (2021).  
668
- 669 61. Crotty, S. A brief history of T cell help to B cells. *Nature reviews. Immunology* **15**, 185-  
670 189 (2015).  
671
- 672 62. van den Berg, S.P.H. *et al.* Latent CMV Infection Is Associated With Lower Influenza  
673 Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response  
674 to Acute Influenza Virus Infection. *Front Immunol* **12** (2021).  
675
- 676 63. Theeten, H. *et al.* Cellular Interferon Gamma and Granzyme B Responses to  
677 Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. *Viral*  
678 *immunology* **29**, 169-175 (2016).  
679
- 680 64. Furman, D. *et al.* Cytomegalovirus infection enhances the immune response to influenza.  
681 *Science translational medicine* **7**, 281ra243 (2015).  
682

- 683 65. Neidleman, J. *et al.* SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper  
684 Function, Lack of Terminal Differentiation, and High Proliferation Potential. *Cell Rep*  
685 *Med* **1**, 100081-100081 (2020).  
686
- 687 66. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans  
688 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e1415 (2020).  
689
- 690 67. Miles, D.J. *et al.* Cytomegalovirus infection in Gambian infants leads to profound CD8  
691 T-cell differentiation. *J Virol* **81**, 5766-5776 (2007).  
692
- 693 68. Felismino, E.S. *et al.* Better Response to Influenza Virus Vaccination in Physically  
694 Trained Older Adults Is Associated With Reductions of Cytomegalovirus-Specific  
695 Immunoglobulins as Well as Improvements in the Inflammatory and CD8+ T-Cell  
696 Profiles. *Front Immunol* **12** (2021).  
697
- 698 69. Rydzynski Moderbacher, C. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2  
699 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996-  
700 1012.e1019 (2020).  
701
- 702 70. Wang, C. *et al.* Effects of aging, cytomegalovirus infection, and EBV infection on human  
703 B cell repertoires. *Journal of immunology (Baltimore, Md. : 1950)* **192**, 603-611 (2014).  
704
- 705 71. Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity  
706 and correlates of severity. *Science* **370** (2020).  
707
- 708 72. Simonnet, A. *et al.* High incidence of Epstein-Barr virus, cytomegalovirus, and human-  
709 herpes virus-6 reactivations in critically ill patients with COVID-19. *Infect Dis Now* **51**,  
710 296-299 (2021).  
711
- 712 73. Alanio, C. *et al.* Cytomegalovirus latent infection is associated with an increased risk of  
713 COVID-19-related hospitalization. *J Infect Dis* (2022).  
714
- 715 74. Del Valle, D.M. *et al.* An inflammatory cytokine signature predicts COVID-19 severity  
716 and survival. *Nature Medicine* **26**, 1636-1643 (2020).  
717

718 **Table 1. Participant Demographics**

	<b>CMV Seronegative</b> (n=74; 17 repeated)	<b>CMV Seropositive</b> (n=159; 30 repeated)	<b>Statistical Assessment</b>
Age (median +/- SD; range)	85 ± 6.8 years (65-93)	86 ± 7.7 years (65-101)	p=0.1265*
Sex (frequency)	67.6% female (n=50)	69.8% female (n=111)	p=0.7618**
Sample Size Post-Dose 2	n=51	n=108	..
2 <sup>nd</sup> Dose Vaccine Combination (frequency)	47.1% Moderna-Moderna (n=24) 52.9% Pfizer-Pfizer (n=27)	35.8% Moderna-Moderna (n=39) 60.6% Pfizer-Pfizer (n=66) 2.75% Pfizer-Moderna (n=3)	p=0.2968**
Days Between Dose 1 and Dose 2 (mean +/- SD)	32.2 ± 20.8 days	30.4 ± 17.9 days	p=0.6697*
Days Since 2 <sup>nd</sup> Dose to Blood Collection (mean +/- SD)	179.8 ± 50.1 days	175.4 ± 64.1 days	p=0.9041*
Sample Size Post-Dose 3	n=23	n=51	..
3 <sup>rd</sup> Dose Vaccine Combination (frequency)	65.2% Moderna-Moderna-Moderna (n=15) 34.8% Pfizer-Pfizer-Pfizer (n=8)	56.9% Moderna-Moderna-Moderna (n=29) 43.1% Pfizer-Pfizer-Pfizer (n=22)	p=0.6115**
Days Between Dose 2 and Dose 3 (mean +/- SD)	203.9 ± 21.0 days	211.7 ± 12.1 days	p=0.2689*
Days Since 3 <sup>rd</sup> Dose to Blood Collection (mean +/- SD)	82.0 ± 17.3 days	83.7 ± 11.5 days	p=0.7597*
Prior COVID-19***	37.8% (n=28)	34.4% (n=55)	p=0.6609*
Only positive for nasopharyngeal PCR test	28.6% (n=8)	36.4% (n=20)	p>0.6244**
Only positive for anti-NC antibodies	39.3% (n=11)	40.0% (n=22)	p>0.9999**
Positive for PCR test and anti-NC antibodies	32.1% (n=9)	23.6% (n=13)	p=0.7977**

719 \*Mann-Whitney U-test or Student's t test by normality; \*\*Fisher's exact test. Comparisons for  
 720 vaccines post-dose 2 were calculated for Moderna-Moderna vs Pfizer-Pfizer. \*\*\* participants were  
 721 considered 'positive' for prior COVID-19 infection in subsequent analyses if they had a recorded  
 722 positive nasopharyngeal PCR test and/or seropositivity for anti-nucleocapsid IgG or IgA  
 723 antibodies.  
 724

725 **Table 2. Responders and non-responders to vaccination by CMV serostatus – antibodies**

Antibody	Vaccine Doses	Total Responder Frequency			Responder Frequency by CMV Seropositivity				
		n	Frequency (%)	p*	Seronegative		Seropositive		p*
					n	Frequency (%)	n	Frequency (%)	
anti-Spike IgG	2	141/159	88.7	0.0415	47/51	92.2	94/108	87.0	0.4287
	3	72/74	97.3		21/23	91.3	51/51	100	0.0937
anti-Spike IgA	2	98/159	61.6	<0.0001	33/51	64.7	65/108	60.2	0.6053
	3	71/74	95.9		21/23	91.3	50/51	98.0	0.2264
anti-Spike IgM	2	20/159	12.6	<0.0001	8/51	15.7	12/108	11.1	0.4476
	3	28/74	37.8		8/23	34.8	20/51	39.2	0.7992
anti-RBD IgG	2	101/159	63.5	<0.0001	34/51	66.7	67/108	62.0	0.6011
	3	70/74	94.6		21/23	91.3	49/51	96.1	0.5837
anti-RBD IgA	2	35/159	22.0	0.0760	12/51	23.5	23/108	21.3	0.8380
	3	25/74	33.8		8/23	13.0	17/51	33.3	>0.9999
anti-RBD IgM	2	6/159	3.77	>0.9999	3/51	5.88	3/108	2.78	0.3863
	3	3/74	4.05		1/23	4.35	2/51	3.92	>0.9999

726 \*Fisher's exact test

727

728 **Table 3. Associations of antibody and neutralization responses after vaccination by CMV serostatus**


	Antibody	MNT50 wildtype		MNT50 beta	
		CMV-ve	CMV+ve	CMV-ve	CMV+ve
Post-Dose 2	IgG Spike	**** r = 0.8367	**** r = 0.8316	**** r = 0.6963	**** r = 0.7541
	IgG RBD	**** r = 0.7394	**** r = 0.8291	**** r = 0.6848	**** r = 0.6981
	IgA Spike	**** r = 0.6222	**** r = 0.6152	**** r = 0.6402	**** r = 0.5254
	IgA RBD	** r = 0.4311	**** r = 0.4572	** r = 0.4813	*** r = 0.3639
Post-Dose 3	IgG Spike	*** r = 0.6923	*** r = 0.5004	*** r = 0.6545	*** r = 0.5038
	IgG RBD	**** r = 0.8207	**** r = 0.5770	**** r = 0.7475	**** r = 0.6926
	IgA Spike	** r = 0.6324	* r = 0.3228	* r = 0.4550	ns
	IgA RBD	**** r = 0.7750	* r = 0.3081	*** r = 0.7051	* r = 0.3575

729

730 **Table 4. Responders and non-responders to vaccination by CMV serostatus – cellular responses**

T cell Population	Vaccine Doses	Total Responder Frequency			Responder Frequency by CMV Seropositivity				
		n	Frequency (%)	p*	Seronegative		Seropositive		p*
					n	Frequency (%)	n	Frequency (%)	
S-CD8+	2	31/159	19.5	0.0943	6/50	12.0	24/108	22.2	0.1898
	3	22/74	29.7		3/23	13.0	19/51	37.3	0.0532
S-CD4+	2	148/159	93.1	0.5570	45/50	90.0	102/108	94.4	0.3262
	3	71/74	95.9		22/23	95.7	49/51	96.1	>0.9999


731 \*Fisher's exact test



732

733 **Figure 1. Antibodies and neutralization capacity by CMV serostatus after two and three**  
 734 **COVID-19 vaccines in older adults.**

735 Serum SARS-CoV-2 anti-Spike and anti-RBD antibodies were detected by ELISA, and antibody  
 736 neutralization capacity was assessed by MNT50 with live SARS-CoV-2 virus. Anti-Spike  
 737 antibodies: IgG (A), IgA (B) and IgM (C). Anti-receptor binding domain (RBD) antibodies: IgG  
 738 (D), IgA (E), and IgM (F). Antibody neutralization capacity was assessed against ancestral (G)  
 739 and beta variant (H) SARS-CoV-2. Dotted lines indicate the threshold of detection. Each data  
 740 point indicates an individual participant, and the center line indicates the median. Associations  
 741 between CMV serostatus and vaccine dose were assessed by two-way ANOVA, with Tukey's  
 742 test post-hoc analysis. \*\*\* $p < 0.001$ , \* $p < 0.0001$ .




743

744 **Figure 2. Effect of CMV serostatus on the circulating T cell repertoire in older adults.**

745 T cell populations in whole blood were assessed by flow cytometry. (A) Relative prevalence of  
746 CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets by CMV serostatus (also see Supplementary Figure 4). Absolute

747 cell counts of: (B) total leukocytes; (C) total CD4<sup>+</sup> T cells; (D) CD8<sup>+</sup> T cells. Absolute cell  
748 counts of CD4<sup>+</sup> T cells: (E) naïve; (F) central memory; (G) effector memory; (H) EMRA; (I)  
749 terminally differentiated. Absolute cell counts of CD8<sup>+</sup> T cells: (J) naive; (K) central memory;  
750 (L) effector memory; (M) EMRA; (N) terminally differentiated. (O) Surface geometric mean  
751 expression of CD57 and CD28 on CD4<sup>+</sup> and CD8<sup>+</sup> T cells by CMV serostatus. Each data point in  
752 B-N indicates an individual participant, and data are presented as box and whisker plots,  
753 minimum to maximum, where the center line indicates the median. The surface marker  
754 expression in O was visualized by concatenating uncompensated events in FlowJo for each  
755 participant and indicated T cell population grouped according to CMV serostatus, and then  
756 geometric mean fluorescence intensity expression data of each CMV group was overlaid onto the  
757 same histogram plot. Associations between T cell subsets and CMV serostatus were assessed by  
758 Student's t test with Welch's correction or Mann-Whitney U test, according to normality.  
759 \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .






760

761 **Figure 3. CD4<sup>+</sup> and CD8<sup>+</sup> T cell activation induced memory responses to SARS-CoV-2**  
762 **Spike peptide pools in older adults.**

763 AIM assays were performed by flow cytometry analysis after whole blood stimulation. (A) Spike  
764 SARS-CoV-2-specific AIM<sup>+</sup>CD8<sup>+</sup> T cells (expressing CD69 and CD137) were measured as a  
765 proportion of total CD8<sup>+</sup> T cells. (B) Spike SARS-CoV-2-specific AIM<sup>+</sup>CD4<sup>+</sup> T cells (expressing  
766 CD25 and OX40L) were measured as a proportion of total CD4<sup>+</sup> T cells. Spike SARS-CoV-2-  
767 specific AIM<sup>+</sup>CD4<sup>+</sup> T cell functional Th1 (C), Th2 (D), and Th17 (E) subsets. Each data point  
768 indicates an individual participant. For A-B data from all individuals is graphed irrespective of  
769 whether they meet cut-off requirements for a ‘positive’ result. For C-E, only data from  
770 individuals with ‘positive’ S-CD4<sup>+</sup> T cell memory responses were graphed. Data are presented as  
771 box and whisker plots, minimum to maximum, where the center line indicates the median.  
772 Associations between CMV serostatus and vaccine dose were assessed by two-way ANOVA,  
773 with Tukey’s test post-hoc analysis. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .





774

775 **Figure 4. CD4<sup>+</sup> and CD8<sup>+</sup> T cell activation induced memory responses to CytoStim and**  
 776 **influenza HA peptide pools in older adults.**

777 AIM assays were performed by flow cytometry analysis after whole blood stimulation.  
 778 CytoStim-induced responses: (A) AIM<sup>+</sup>CD8<sup>+</sup> T cells (expressing CD69 and CD137) as a  
 779 proportion of total CD8<sup>+</sup> T cells; (B) AIM<sup>+</sup>CD4<sup>+</sup> T cells (expressing CD25 and OX40L) as a  
 780 proportion of total CD4<sup>+</sup> T cells; AIM<sup>+</sup>CD4<sup>+</sup> T cell functional Th1 (C), Th2 (D), and Th17 (E)  
 781 subsets. Influenza HA-induced responses: (F) AIM<sup>+</sup>CD8<sup>+</sup> T cells (expressing CD69 and CD137)  
 782 as a proportion of total CD8<sup>+</sup> T cells; (G) AIM<sup>+</sup>CD4<sup>+</sup> T cells (expressing CD25 and OX40L) as a  
 783 proportion of total CD4<sup>+</sup> T cells; AIM<sup>+</sup>CD4<sup>+</sup> T cell functional Th1 (H), Th2 (I), and Th17 (J)  
 784 subsets. Each data point indicates an individual participant. Data is pooled from all blood  
 785 collections, and for participants with two different collection time points, data are only included  
 786 from post-dose 2 collections. Data are presented as box and whisker plots, minimum to  
 787 maximum, where the center line indicates the median. Associations between T cell responses  
 788 CMV serostatus were assessed by Student's t test with Welch's correction or Mann-Whitney U  
 789 test, according to normality. \* $p < 0.01$ , \*\* $p < 0.001$ , \*\*\* $p < 0.0001$ .